Preliminary findings from the PREOPANC-1 trial suggest that neoadjuvant chemoradiotherapy may be beneficial for patients with resectable pancreatic cancer. Lead author Geertjan Van Tienhoven outlines the results and discusses the challenges of conducting this trial. (3:46)
08-06-2018 | Pancreatic cancer | ASCO 2018 | Video